Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...
CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...
Guardant Health’s SHIELD test received ADLT status, expected to increase its average selling price (ASP) significantly. The company anticipates substantial growth for Reveal, especially with ...
Guardant Health’s SHIELD test received ADLT status, expected to increase its average selling price (ASP) significantly. The company anticipates substantial growth for Reveal, especially with expanded ...
Guardant Reveal, in favor of its own product, Signatera. Guardant’s Shield became the first blood test approved by the FDA as a primary screening option for colorectal cancer. The current lawsuit ...
The firm’s confidence in the stock is supported by the strong performance of Guardant Health’s G360 core, the growing momentum of the Reveal test, and the potential of the Shield test in the ...
The firm’s confidence in the stock is supported by the strong performance of Guardant Health’s G360 core, the growing momentum of the Reveal test, and the potential of the Shield test in the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback